These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18507552)

  • 1. Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: a case report.
    Murdock DK; Kaliebe J; Overton N
    Pacing Clin Electrophysiol; 2008 Jun; 31(6):765-8. PubMed ID: 18507552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of non-sustained ventricular tachycardia with ranolazine: a case report.
    Kaliebe JW; Murdock DK
    WMJ; 2009 Oct; 108(7):373-5. PubMed ID: 19886587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranolazine--treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy.
    Nanda S; Levin V; Martinez MW; Freudenberger R
    Pacing Clin Electrophysiol; 2010 Dec; 33(12):e119-20. PubMed ID: 20345626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ranolazine in a patient with idiopathic dilated cardiomyopathy and electrical storm.
    Vizzardi E; D'Aloia A; Salghetti F; Aljassim O; Raweh A; Bonadei I; Bontempi L; Curnis A
    Drug Discov Ther; 2013 Feb; 7(1):43-5. PubMed ID: 23524943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series.
    Murdock DK; Kaliebe J; Larrain G
    Pacing Clin Electrophysiol; 2012 Mar; 35(3):302-7. PubMed ID: 22229482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ablation of ventricular tachycardia in patients with nonischemic cardiomyopathy.
    Bogun F; Morady F
    J Cardiovasc Electrophysiol; 2008 Nov; 19(11):1227-30. PubMed ID: 18691235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranolazine and its anti-ischemic effects: revisiting an old mechanistic paradigm anew?
    Boden WE
    J Am Coll Cardiol; 2010 Sep; 56(12):943-5. PubMed ID: 20828646
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart.
    Kumar K; Nearing BD; Bartoli CR; Kwaku KF; Belardinelli L; Verrier RL
    J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1073-9. PubMed ID: 18479333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.
    Stone PH
    Cardiol Clin; 2008 Nov; 26(4):603-14. PubMed ID: 18929234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranolazine for the suppression of ventricular arrhythmia: a case series.
    Yeung E; Krantz MJ; Schuller JL; Dale RA; Haigney MC
    Ann Noninvasive Electrocardiol; 2014 Jul; 19(4):345-50. PubMed ID: 24533675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranolazine is effective for acute or chronic ischemic dysfunction with heart failure.
    Nanda S; Martinez MW; Dey T
    J Am Coll Cardiol; 2010 Aug; 56(10):822; author reply 822. PubMed ID: 20797499
    [No Abstract]   [Full Text] [Related]  

  • 12. Ranolazine and silent ischemia.
    Conti CR
    J Am Coll Cardiol; 2011 Aug; 58(10):1083; author reply 1083-4. PubMed ID: 21867850
    [No Abstract]   [Full Text] [Related]  

  • 13. Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia.
    Zhang XQ; Yamada S; Barry WH
    J Cardiovasc Pharmacol; 2008 May; 51(5):443-9. PubMed ID: 18398379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
    Sossalla S; Maier LS
    Pharmacol Ther; 2012 Mar; 133(3):311-23. PubMed ID: 22133843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranolazine: a new option in the management of chronic stable angina.
    Dobesh PP; Trujillo TC
    Pharmacotherapy; 2007 Dec; 27(12):1659-76. PubMed ID: 18041887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction.
    Wu Y; Song Y; Belardinelli L; Shryock JC
    J Pharmacol Exp Ther; 2009 Aug; 330(2):550-7. PubMed ID: 19403851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart.
    Kumar K; Nearing BD; Carvas M; Nascimento BC; Acar M; Belardinelli L; Verrier RL
    J Cardiovasc Electrophysiol; 2009 Jul; 20(7):796-802. PubMed ID: 19298570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application.
    Hwang H; Arcidi JM; Hale SL; Simkhovich BZ; Belardinelli L; Dhalla AK; Shryock JC; Kloner RA
    J Cardiovasc Pharmacol Ther; 2009 Jun; 14(2):125-33. PubMed ID: 19329672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid treatment deteriorated ventricular tachycardia in a patient with right ventricle-dominant cardiac sarcoidosis.
    Hiramastu S; Tada H; Naito S; Oshima S; Taniguchi K
    Int J Cardiol; 2009 Feb; 132(2):e85-7. PubMed ID: 18037174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts.
    Hwang H; Arcidi JM; Hale SL; Simkhovich BZ; Belardinelli L; Dhalla AK; Shryock JC; Kloner RA
    Circulation; 2009 Sep; 120(11 Suppl):S16-21. PubMed ID: 19752362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.